BRIAN REECE: Open Payments
NPI 1568089084 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$679 in 31 payments from 15 companies in 2025. Trend: 2023 $392 · 2024 $491 · 2025 $679
Food & beverage: $679
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $105 |
| Novartis Pharmaceuticals Corporation | 3 | $82 |
| GENZYME CORPORATION | 2 | $69 |
| UCB, Inc. | 3 | $68 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| LEO Pharma Inc. | 3 | $51 |
| Janssen Biotech, Inc. | 2 | $40 |
| Galderma Laboratories, L.P. | 2 | $34 |
| PFIZER INC. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
Products named: Otezla, DUPIXENT, COSENTYX, Bimzelx, Sotyktu, TREMFYA, ADBRY, NEMLUVIO.
Industry payments across NV — which companies pay providers there.
